VSIG8 | V-set and immunoglobulin domain containing 8 | Predicted membrane proteins
| | | | | Group enriched |
AC023590.1 | Uncharacterized protein | | | | | | Tissue enhanced |
AC129492.6 | | | | | | | Tissue enhanced |
AIM2 | Absent in melanoma 2 | | | | | | Tissue enhanced |
ARHGAP25 | Rho GTPase activating protein 25 | Plasma proteins
| | | | | Tissue enhanced |
ATP12A | ATPase, H+/K+ transporting, nongastric, alpha polypeptide | Enzymes Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
AURKB | Aurora kinase B | Cancer-related genes Disease related genes Enzymes Plasma proteins Potential drug targets
| | | | | Tissue enhanced |
BACH2 | BTB and CNC homology 1, basic leucine zipper transcription factor 2 | Plasma proteins Transcription factors
| | | | | Tissue enhanced |
BANK1 | B-cell scaffold protein with ankyrin repeats 1 | Disease related genes
| | | | | Tissue enhanced |
BFSP2 | Beaded filament structural protein 2, phakinin | Disease related genes
| | | | | Tissue enhanced |
BTK | Bruton agammaglobulinemia tyrosine kinase | Disease related genes Enzymes Plasma proteins Potential drug targets
| | | | | Tissue enhanced |
BTN1A1 | Butyrophilin, subfamily 1, member A1 | Predicted membrane proteins
| | | | | Tissue enhanced |
CCL19 | Chemokine (C-C motif) ligand 19 | Cancer-related genes Predicted secreted proteins
| | | | | Tissue enhanced |
CCL20 | Chemokine (C-C motif) ligand 20 | Predicted secreted proteins
| | | | | Tissue enhanced |
CCL21 | Chemokine (C-C motif) ligand 21 | Cancer-related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CCL22 | Chemokine (C-C motif) ligand 22 | Predicted secreted proteins
| | | | | Tissue enhanced |
CCR6 | Chemokine (C-C motif) receptor 6 | CD markers G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
CD180 | CD180 molecule | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
CD1C | CD1c molecule | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
CD22 | CD22 molecule | CD markers Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD27 | CD27 molecule | Cancer-related genes CD markers Disease related genes Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CD3D | CD3d molecule, delta (CD3-TCR complex) | CD markers Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD3E | CD3e molecule, epsilon (CD3-TCR complex) | CD markers Disease related genes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
CD3G | CD3g molecule, gamma (CD3-TCR complex) | CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD40LG | CD40 ligand | Cancer-related genes Candidate cardiovascular disease genes CD markers Disease related genes Predicted membrane proteins
| | | | | Tissue enhanced |
CD48 | CD48 molecule | CD markers Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD6 | CD6 molecule | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD79A | CD79a molecule, immunoglobulin-associated alpha | Cancer-related genes CD markers Disease related genes Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD79B | CD79b molecule, immunoglobulin-associated beta | Cancer-related genes CD markers Disease related genes Predicted membrane proteins
| | | | | Tissue enhanced |
CD80 | CD80 molecule | CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CDC20 | Cell division cycle 20 | Cancer-related genes Plasma proteins
| | | | | Tissue enhanced |
CH17-132F21.1 | Uncharacterized protein | Predicted secreted proteins
| | | | | Tissue enhanced |
CHI3L2 | Chitinase 3-like 2 | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CLEC4C | C-type lectin domain family 4, member C | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
CLECL1 | C-type lectin-like 1 | Predicted membrane proteins
| | | | | Tissue enhanced |
CPNE5 | Copine V | Plasma proteins
| | | | | Tissue enhanced |
CSF2RB | Colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage) | CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CSTA | Cystatin A (stefin A) | Cancer-related genes Disease related genes Plasma proteins
| | | | | Tissue enhanced |
CTB-133G6.1 | | Predicted membrane proteins
| | | | | Tissue enhanced |
CTLA4 | Cytotoxic T-lymphocyte-associated protein 4 | CD markers Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CXCR4 | Chemokine (C-X-C motif) receptor 4 | Cancer-related genes CD markers Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
CYTIP | Cytohesin 1 interacting protein | | | | | | Tissue enhanced |
DEFB103A | Defensin, beta 103A | Predicted secreted proteins Transporters
| | | | | Tissue enhanced |
DEFB103B | Defensin, beta 103B | Predicted secreted proteins Transporters
| | | | | Tissue enhanced |
DTX1 | Deltex homolog 1 (Drosophila) | | | | | | Tissue enhanced |
ELL3 | Elongation factor RNA polymerase II-like 3 | | | | | | Tissue enhanced |
EML6 | Echinoderm microtubule associated protein like 6 | | | | | | Tissue enhanced |
FAIM3 | Fas apoptotic inhibitory molecule 3 | Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
FAM111B | Family with sequence similarity 111, member B | Disease related genes
| | | | | Tissue enhanced |
FAM72C | Family with sequence similarity 72, member C | | | | | | Tissue enhanced |